BRM
ABBV icon

Boston Research & Management’s AbbVie ABBV Stock Holding History

Boston Research & Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.5M Sell
48,353
-335
-0.7% -$74.3K 2.5% 6
2025
Q4 		$11.1M Sell
48,688
-2,450
-5% -$558K 2.57% 6
2025
Q3 		$11.8M Sell
51,138
-50
-0.1% -$10.2K 2.61% 6
2025
Q2 		$9.5M Buy
51,188
+330
+0.6% +$61.3K 2.27% 8
2025
Q1 		$10.7M Sell
50,858
-1,278
-2% -$248K 2.65% 6
2024
Q4 		$9.26M Sell
52,136
-102
-0.2% -$18.8K 2.27% 8
2024
Q3 		$10.3M Sell
52,238
-175
-0.3% -$32.7K 2.42% 7
2024
Q2 		$8.99M Sell
52,413
-624
-1% -$103K 2.27% 8
2024
Q1 		$9.66M Sell
53,037
-715
-1% -$123K 2.39% 6
2023
Q4 		$8.33M Buy
53,752
+595
+1% +$86.7K 2.21% 6
2023
Q3 		$7.92M Sell
53,157
-55
-0.1% -$8.07K 2.34% 6
2023
Q2 		$7.17M Buy
53,212
+30
+0.1% +$4.4K 2.03% 11
2023
Q1 		$8.47M Sell
53,182
-536
-1% -$81.9K 2.53% 5
2022
Q4 		$8.68M Sell
53,718
-1,159
-2% -$178K 2.69% 3
2022
Q3 		$7.37M Sell
54,877
-217
-0.4% -$31.1K 2.51% 5
2022
Q2 		$8.44M Sell
55,094
-1,252
-2% -$191K 2.73% 3
2022
Q1 		$9.13M Sell
56,346
-2,317
-4% -$337K 2.65% 5
2021
Q4 		$7.94M Sell
58,663
-195
-0.3% -$23K 2.17% 10
2021
Q3 		$6.35M Buy
58,858
+775
+1% +$88.6K 1.89% 15
2021
Q2 		$6.54M Sell
58,083
-155
-0.3% -$17.5K 1.98% 14
2021
Q1 		$6.3M Buy
58,238
+580
+1% +$62K 2.03% 12
2020
Q4 		$6.18M Buy
57,658
+917
+2% +$88.1K 2.15% 12
2020
Q3 		$4.97M Sell
56,741
-1,461
-3% -$138K 1.94% 17
2020
Q2 		$5.71M Buy
58,202
+271
+0.5% +$23.9K 2.37% 9
2020
Q1 		$4.41M Sell
57,931
-777
-1% -$66.2K 2.22% 12
2019
Q4 		$5.2M Sell
58,708
-301
-0.5% -$25K 1.95% 15
2019
Q3 		$4.47M Buy
59,009
+2,985
+5% +$205K 1.77% 23
2019
Q2 		$4.07M Buy
56,024
+1,120
+2% +$88K 1.65% 28
2019
Q1 		$4.42M Buy
54,904
+3,485
+7% +$285K 1.84% 20
2018
Q4 		$4.74M Buy
51,419
+5,930
+13% +$521K 2.26% 7
2018
Q3 		$4.3M Sell
45,489
-830
-2% -$78.7K 1.97% 15
2018
Q2 		$4.29M Sell
46,319
-245
-0.5% -$23.9K 2.11% 8
2018
Q1 		$4.41M Sell
46,564
-3,875
-8% -$426K 2.25% 7
2017
Q4 		$4.88M Sell
50,439
-2,430
-5% -$229K 2.45% 4
2017
Q3 		$4.7M Sell
52,869
-10
-0% -$761 2.4% 3
2017
Q2 		$3.83M Sell
52,879
-70
-0.1% -$4.71K 2.07% 11
2017
Q1 		$3.45M Buy
52,949
+315
+0.6% +$19.8K 1.88% 18
2016
Q4 		$3.29M Buy
52,634
+610
+1% +$37.2K 1.87% 18
2016
Q3 		$3.28M Buy
52,024
+430
+0.8% +$27.8K 1.9% 17
2016
Q2 		$3.19M Buy
51,594
+845
+2% +$51.5K 1.94% 15
2016
Q1 		$2.9M Buy
50,749
+1,605
+3% +$89.5K 1.8% 22
2015
Q4 		$2.91M Buy
49,144
+2,630
+6% +$151K 1.81% 19
2015
Q3 		$2.53M Sell
46,514
-25
-0.1% -$1.63K 1.67% 24
2015
Q2 		$3.13M Buy
46,539
+70
+0.2% +$4.57K 1.98% 11
2015
Q1 		$2.72M Buy
46,469
+10,470
+29% +$633K 1.73% 25
2014
Q4 		$2.35M Buy
35,999
+70
+0.2% +$4.41K 1.48% 32
2014
Q3 		$2.08M Buy
35,929
+5,075
+16% +$282K 1.4% 36
2014
Q2 		$1.74M Buy
30,854
+3,282
+12% +$172K 1.2% 45
2014
Q1 		$1.42M Buy
27,572
+169
+0.6% +$8.54K 1.04% 47
2013
Q4 		$1.45M Buy
27,403
+535
+2% +$26.3K 1.11% 46
2013
Q3 		$1.2M Buy
26,868
+3,709
+16% +$164K 1.01% 49
2013
Q2 		$957K Buy
+23,159
New +$1.01M 0.85% 51

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boston Research & Management's ABBV Position: Q1 2026 in Review

Boston Research & Management reduced its AbbVie (ABBV) stake by 0.69% in Q1 2026, selling an estimated $74.3K and leaving 48,353 shares worth $10.5M. The position accounts for 2.5% of the portfolio, ranked #6.

Boston Research & Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $11.8M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Boston Research & Management held 48,353 shares of AbbVie worth $10.5M as of Q1 2026.
  • Boston Research & Management sold 335 AbbVie shares in Q1 2026, an estimated $74.3K.
  • AbbVie made up 2.5% of Boston Research & Management's portfolio in Q1 2026, its #6 holding.
  • Boston Research & Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Boston Research & Management's AbbVie position peaked at $11.8M in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Boston Research & Management's 13F filing for Q1 2026, filed 10 Apr 2026.